MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-12-2025
Veru Accounts Receivables 2011-2025 | VERU
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Veru
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.96 M | 4.51 M | 3.55 M | 8.79 M | 5.23 M | 5.02 M | 3.97 M | 11.4 M | 18.6 M | 14.1 M | 2.94 M | 2.36 M | 7.21 M | 2.31 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 18.6 M | 2.31 M | 6.71 M |
Quarterly Accounts Receivables Veru
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 1.64 M | 2.79 M | 2.38 M | 4.51 M | 5.08 M | 4.21 M | 3.86 M | 3.55 M | 8.3 M | 8.13 M | 8.07 M | 8.79 M | 8.31 M | 8.79 M | 4.16 M | 5.23 M | 5.23 M | 5.23 M | 5.97 M | 5.02 M | 5.02 M | 5.02 M | 2.49 M | 3.97 M | 3.97 M | 3.97 M | 3 M | 11.3 M | 11.4 M | 11.4 M | 8.39 M | 18.6 M | 10.8 M | 10.8 M | 17.7 M | 14.1 M | 14.1 M | 14.1 M | 5.84 M | 2.94 M | 2.94 M | 2.94 M | 2.67 M | 2.36 M | 2.36 M | 2.36 M | 7.84 M | 7.27 M | 7.27 M | 7.27 M | 4.79 M | 2.31 M | 2.31 M | 2.31 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 18.6 M | 1.64 M | 6.39 M |
Accounts Receivables of other stocks in the Drug manufacturers industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
34.5 M | - | - | $ 142 M |  USA |
 |
Assertio Holdings
ASRT
|
47.7 M | $ 0.73 | -3.6 % | $ 51.9 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
68.8 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
47.5 M | $ 1.7 | -2.59 % | $ 183 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
160 K | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
1.05 M | - | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
3.39 M | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
921 M | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
1.26 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
72.4 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
387 M | - | - | $ 28.9 M |  Irlanda |
 |
Emergent BioSolutions
EBS
|
191 M | $ 12.37 | 8.32 % | $ 633 M | USA |
 |
Evoke Pharma
EVOK
|
673 K | $ 10.96 | 0.09 % | $ 36.6 M | USA |
 |
Athenex
ATNX
|
27.9 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
34.1 M | $ 21.43 | 0.3 % | $ 2.04 B |  France |
 |
Evolus
EOLS
|
47.7 M | $ 7.18 | 1.99 % | $ 445 M | USA |
 |
Harrow Health
HROW
|
15.1 M | $ 46.29 | -1.64 % | $ 1.51 B | USA |
 |
China Pharma Holdings
CPHI
|
232 K | $ 1.53 | -1.92 % | $ 26.7 M |  China |
 |
Bausch Health Companies
BHC
|
2 B | $ 6.9 | -0.36 % | $ 2.52 B | Canada |
 |
Organogenesis Holdings
ORGO
|
110 M | $ 4.78 | -0.83 % | $ 629 M | USA |
 |
Lannett Company
LCI
|
56.2 M | - | 1.15 % | $ 7.11 M | USA |
 |
Pacira BioSciences
PCRX
|
113 M | $ 26.61 | 1.22 % | $ 1.23 B | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
11.7 M | $ 3.11 | 22.92 % | $ 43.7 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
65.4 K | - | - | $ 193 M | Canada |
 |
Rockwell Medical
RMTI
|
10.9 M | $ 0.88 | -5.3 % | $ 20.5 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
2.23 M | $ 3.55 | -1.11 % | $ 4.41 M | USA |
 |
PetIQ
PETQ
|
143 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
512 K | $ 4.34 | 6.91 % | $ 131 M | USA |
 |
Jupiter Wellness
JUPW
|
512 K | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
642 M | $ 12.77 | -2.78 % | $ 1.75 B | USA |
 |
ProPhase Labs
PRPH
|
37.1 M | $ 0.11 | -0.35 % | $ 1.74 M | USA |
 |
Radius Health
RDUS
|
20.3 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
16.6 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
19.9 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
634 K | - | -27.8 % | $ 2.56 M | USA |
 |
cbdMD
YCBD
|
622 K | $ 1.19 | -0.83 % | $ 5.13 M | USA |
 |
SCYNEXIS
SCYX
|
2.1 M | $ 0.64 | -0.91 % | $ 30.6 M | USA |
 |
Tilray
TLRY
|
86.2 M | $ 11.01 | -9.4 % | $ 6.8 B | Canada |
 |
TherapeuticsMD
TXMD
|
32.4 M | $ 1.7 | -2.86 % | $ 17.7 M | USA |
 |
Zomedica Corp.
ZOM
|
1.2 M | - | -0.21 % | $ 98 M | USA |
 |
Viatris
VTRS
|
3.24 B | $ 11.68 | 0.29 % | $ 14.2 B | USA |